|
|
OnDemand: Improved Strategies for Pre-Clinical Cardiac Testing (Jun 23)
Register for the On-Demand version of DSEC’s complimentary webinar and panel by submitting your information below. Please note that by registering to access this recording, you are giving DSEC permission to provide your contact information to ChanTest, the sponsor of this webinar.
On-Demand Webinar and Panel
This webinar entitled: Improved Strategies for Pre-Clinical Cardiac Testing took place Wednesday, June 23, 2010 from 11:00AM-12:00PM EDT (5:00 p.m. CEST). This session was supported by:
The panel addressed such questions as:
- What is the importance of additional assays beyond the S7B recommendations, and what impact would these have on drug development costs?
- There is considerable interest in the use of stem cell-derived cardiomyocytes for drug development. How can this technology be used to improve cardiac safety predictivity, and would it replace current assays or augment them?
- How would you see new assays or technologies implemented into current workflows to improve cardiac safety predictivity?
- What is the most underutilized test available today for determining cardiac safety that should be considered for better predictivity?
- If technologies are available today that can virtually eliminate questions on a compound's future safety risk, what are the drivers preventing their use in drug development today?
The expert panel included the following:
* David J. Gallacher, Bsc, Ph.D., Senior Director, Center of Excellence for Cardiovascular Safety Research, Johnson & Johnson Pharmaceutical Research & Development, a Division of Jansen Pharmaceutica
* Gary Gintant, Ph.D, Senior Group Leader, Department of Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories
* Arthur Brown, M.D., Ph.D, President & CEO, ChanTest Corporation
|